MUMBAI, March 8- Indian drugmaker Ranbaxy Laboratories Ltd, reeling under a flurry of regulatory rebukes due to poor quality, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after doseage mix-up was detected.» Read More
AstraZeneca has agreed to buy U.S. biotechnology company MedImmune for more than $15 billion in the biggest transaction since the creation of the Anglo-Swedish drugs group in 1999.
Mylan Laboratories spacer said U.S. regulators approved its generic version of Sanofi-Aventis' sleeping pill, Ambien, in the 5 mg and 10 mg strengths.
In a previous blog post, I wrote about what happened at this year's American College of Cardiology conference in New Orleans when at least one doctor "leaked" the results of a major, highly anticipated study comparing drug-coated stents to old-fashioned heart drugs. The ACC had to move up the embargo time of the data by one day and reporters had to scramble to meet the hastened deadline.
Demand for a free vaccine against cervical cancer is outstripping supply in New Hampshire, which was the first state in the country to approve free distribution of the vaccine, which protects girls against four strains of a sexually transmitted infection called human papillomavirus, or HPV.
Strong sales of its flagship drugs boosted net profit at Swiss drugmaker Novartis by 11% to $2.171 billion, the group said on Monday, confounding expectations for a weaker profit.
Earnings blowouts from Google and strong guidance from two key names in the industrial sector were among the catalysts for Friday's most-active stocks.
The average markup or premium paid in a biotech M & A deal worth at least $500 million in 2006 was 60%. 60%! That's one of the most startling numbers you'll find in Ernst & Young's 21st Annual "Global Biotechnology Report".
Gardasil -- Merck's new vaccine for HPV and cervical cancer -- has been a lightning rod for social controversy since it came to market in the second half of last year. Should Merck be lobbying state's to mandate it? Should parents be forced to have their pre-adolescent, presumably pre-sexually-active kids to get it? Who will pay for it? (It costs about $400 for all three shots which are given over several months.)
Good morning. Serge Amelyan continues to hold the top position on the overall leaderboard, while the upset occurs as Parker Robinson falls to third, displaced by Vitaliy Khizder who moves into 2nd. As we said Thursday, Serge is the first contestant to break the $3M mark with a total portfolio value of $3,275,721.77 up $39,498.72 from Wednesday's total on the sale of...
Amgen fools us: One of my favorite exercises at the Breaking News Desk is to figure out whether something is news, and how it might move the stock involved. This morning, a headline moved regarding Amgen’s anemia drug Aranesp. I’m not a pharmaceutical expert -- that’s why we have reporter Mike Huckman -- but since it involved a very large company and a drug I’d actually heard of, we knew it was news. Here’s where it got interesting...
Shares of Amgen surged after the biotech giant said that its anemia drug Aranesp showed no difference in risk of death compared with a placebo in a closely watched study of the medicine in small-cell lung cancer patients.
Here's our re-cap of today--with the leaderboard, most active and widely held stocks as well as our trivia questions. We'll start there. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%.
Wow--we've gotten posts from all three guest bloggers today as this one from Timothy Sykes wraps it up. You certainly have some food for thought. Here's Timothy: Many contestants have been asking why I advocate such a seemingly risky strategy by focusing on chart plays with upcoming earnings. The answer, like my strategy, is rather simple.
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
Hey folks, time for the day's trivia questions. Here they are. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%. The news trivia question is worth $1,000 Bonus Bucks: Merck reported that revenue climbed from the same quarter last year, boosted in part by sales of what cholesterol drug? The selection of answers are: Lipitor or Plavix or Zetia or Remicade.
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.
Wyeth said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.
Merck said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.
Good morning all. Serge Amelyan maintains his lead for the second day running, and Parker Robinson holds 2nd place--as both gain substantially with the top trade of the day on Linear Technology. It was was up 12.20% Wednesday on strong earnings. AND Serge is the first contestant to break the $3M mark with a total portfolio value of $3,236,223.05 up $351,671.04 from Tuesday's total on the sale of Linear Technology.